Targeting Differentiated Pathways Across Retinal Disease


Pipeline

A Pipeline Built on Novel Retinal Pathways

Program Therapeutic Approach Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Commercial Rights
Diseases of Retinal Ischemia
KIO-401 Calpain Inhibitor CRAO KIO-401 · Calpain Inhibitor Commercial rights: Global Rights (outside Asia) Global Rights
(outside Asia)
NAION KIO-401 · Calpain Inhibitor Commercial rights: Global Rights (outside Asia)
Inherited Retinal Disease
KIO-301 Molecular Photoswitch Retinitis Pigmentosa
(advanced)
KIO-301 · Molecular Photoswitch Commercial rights: Partnered Globally
Partnered
Globally
Other Inherited
Retinal Diseases
KIO-301 · Molecular Photoswitch Commercial rights: Partnered Globally

KIO-401 received Orphan Drug Designation (USA) for CRAO.
KIO-301 received Orphan Drug Designation (USA – March 2022) and Orphan Medicinal Product Designation (EU – July 2024).